Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?

Matteo Rosellini; Andrea Marchetti; Elisa Tassinari; Veronica Mollica; Francesco Massari; Matteo Santoni

doi:10.1080/14712598.2024.2369190

Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?

Expert Opin Biol Ther. 2024 Jun;24(6):411-414. doi: 10.1080/14712598.2024.2369190. Epub 2024 Jun 19.

Authors

Matteo Rosellini^{1

2}, Andrea Marchetti^{1

2}, Elisa Tassinari^{1

2}, Veronica Mollica^{1

2}, Francesco Massari^{1

2}, Matteo Santoni³

Affiliations

¹ Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
² Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
³ Oncology Unit, Macerata Hospital, Macerata, Italy.

PMID: 38898658
DOI: 10.1080/14712598.2024.2369190

No abstract available

Keywords: ILT-4; LAG-3; PD-1; PD-L1; TIGIT; immune checkpoint inhibitors; immune-based combinations; kidney cancer; renal cell carcinoma; toripalimab; volrustomig; zimberelimab.

Publication types

Editorial

MeSH terms

Carcinoma, Renal Cell* / drug therapy
Humans
Immune Checkpoint Inhibitors* / therapeutic use
Kidney Neoplasms* / drug therapy
Kidney Neoplasms* / pathology
Programmed Cell Death 1 Receptor* / antagonists & inhibitors
Programmed Cell Death 1 Receptor* / immunology

Substances

Immune Checkpoint Inhibitors
Programmed Cell Death 1 Receptor
PDCD1 protein, human